DK2938352T3 - Cykliske kationiske peptider med antibmikrobiel aktivitet - Google Patents

Cykliske kationiske peptider med antibmikrobiel aktivitet Download PDF

Info

Publication number
DK2938352T3
DK2938352T3 DK13828804.8T DK13828804T DK2938352T3 DK 2938352 T3 DK2938352 T3 DK 2938352T3 DK 13828804 T DK13828804 T DK 13828804T DK 2938352 T3 DK2938352 T3 DK 2938352T3
Authority
DK
Denmark
Prior art keywords
spp
lys
peptide
amino acids
arg
Prior art date
Application number
DK13828804.8T
Other languages
English (en)
Inventor
Antonello Romani
Maria Cristina Baroni
Clotilde Silvia Cabassi
Original Assignee
Icf Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2938352(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icf Srl filed Critical Icf Srl
Application granted granted Critical
Publication of DK2938352T3 publication Critical patent/DK2938352T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (15)

1. Peptid, der består af en sekvens A-B-C-D-C'-B'-A', hvor: enhed A består af 2 aminosyrer, og enhed A' består af 1 aminosyre, enhederne B og B' begge er Cys, hver enhed C uafhængigt består af 5 aminosyrer, valgt både i gruppe (a) af hydrofobe aminosyrer og i gruppe (b) af basiske aminosyrer eller aminosyrer, der danner hydrogenbindinger; enhed D er -Arg-Gly-, hvor: (i) de hydrofobe aminosyrer er valgt fra: Ala, Phe, lieu, Leu, Pro, Tyr, Trp og Val; (ii) de basiske aminosyrer er valgt fra: Lys, His, Arg; (iii) de aminosyrer, der danner hydrogenbindinger, er valgt fra Asn, Gin, Ser, Thr; og hvor understrukturen C-D-C' som en helhed indeholder 5 til 9 vekslingspunkter mellem aminosyre af gruppe (a) og aminosyre af gruppe (b) eller omvendt, hvor peptidet er i den cykliserede form via dannelse af en disulfidbro mellem de to enheder B, og hvor de hydrofobe aminosyrer er mellem 30 og 50 % af det totale antal af peptidets aminosyrer, hvor peptidet er til anvendelse i behandling af infektioner i menneske- eller dyrekroppen forårsaget af bakterier, svampe og/eller gær.
2. Peptid til anvendelse ifølge krav 1, hvor de hydrofobe aminosyrer er mellem 35 og 45 % af det totale antal af peptidets aminosyrer.
3. Peptid til anvendelse ifølge krav 1 eller 2, hvor mindst én af enhederne C og C omfatter Lys.
4. Peptid til anvendelse ifølge et hvilket som helst af kravene 1 -3, hvor begge enheder C og C' omfatter Lys.
5. Peptid til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor aminosyren stødende op til Gly af enhed D er en hydrofob aminosyre.
6. Peptid til anvendelse ifølge krav 5, hvor aminosyren stødende op til Gly af enhed D er en hydrofob aromatisk aminosyre.
7. Peptid til anvendelse ifølge krav 1, hvor mindst én af enhederne C og C omfatter Lys, og samtlige aminosyrer ved positionerne 6, 8, 13 (nummereret fra A til A') hører til gruppen (i) af hydrofobe aminosyrer.
8. Peptid til anvendelse ifølge krav 7, hvor ligeledes aminosyren ved position 11 hører til gruppen (i) af hydrofobe aminosyrer.
9. Peptid til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor enhederne A og A' omfatter, uafhængigt af hinanden, én eller flere aminosyrer udvalgt fra His, Lys, Gly, Tyr, Ala, Val.
10. Peptid til anvendelse ifølge krav 1, udvalgt fra SEQ ID NO: 1-54 og homologer af hver af SEQ ID NO: 1-54, kendetegnet ved, at homologerne kun er modificeret for én aminosyre ved en hvilken som helst position mellem NO: 1 og 17, hvor modifikationen ikke involverer aminosyrer ved positionerne 3, 9, 10, 16, og modifikationen består i at substituere en aminosyre med en anden aminosyre, der hører til den samme gruppe (a) eller (b).
11. Peptid til anvendelse ifølge krav 10, udvalgt fra SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3.
12. Peptid til anvendelse ifølge et hvilket som helst af kravene 1-11 i behandlingen af infektioner af én eller flere af Staphylococcus spp., for eksempel, Staphylococcus aureus (f.eks. Staphylococcus aureus ATCC 25923), Enterococcus spp., for eksempel, Enterococcus faecalis; Pseudomonas spp., for eksempel Pseudomonas aeruginosa ATCC 27853; Mycobacterium spp., for eksempel Mycobacterium tuberculosis; Enterobacter spp.; Campylobacter spp.;. Salmonella spp.; Streptococcus spp., for eksempel Streptococcus-gruppe A eller B, Streptoccocus pneumoniae, Helicobacter spp., for eksempel Helicobacter pylori; Neisseria spp., for eksempel Neisseria gonorrea, Neisseria meningitidis; Borrelia burgdorferi, Shigella spp., for eksempel, Shigella flexneri; Escherichia coli (ATCC 25922); Haemophilus spp., for eksempel Haemophilus influenzae; Francisella tularensis, Bacillus spp., for eksempel Bacillus anthracis; Clostridia spp., Clostridium botulinum, Yersinia spp., for eksempel, Yersinia pestis; Treponema spp.; Burkholderia spp.; for eksempel Burkholderia cepacia, B. mallei og B pseudomallei; Stenotrophomonas spp., for eksempel Stenotrophomonas maltophilia; Candida spp. (for eksempel C. albicans), Epidermophyton spp., Exophiala spp., Microsporum spp., Trichophyton spp. (for eksempel T. rubrum og T. interdigitale), Tinea spp., Aspergillus spp., Blastomyces spp., Blastoschizomyces spp., Coccidioides spp., Cryptococcus spp. (for eksempel Cryptococcus neoformans), Histoplasma spp., Paracoccidiomyces spp., Sporotrix spp., Absidz spp., Cladophialophora spp., Fonsecaea spp., Phialophora spp., Lacazia spp., Ari rographis spp., Acremonium spp., Actinomadura spp., Apophysomyces spp., Emmonsia spp., Basidiobolus spp., Beauveria spp., Chrysosporium spp., Conidiobolus spp., Cunninghamella spp., Fusarium spp., Geotrichum spp., Graphium spp., Leptosphaeria spp., Maiassezia spp., (for eksempel Malassezia furfur), Mucor spp., Neotestudina spp., Nocardia spp., Nocardiopsis spp., Paecilomyces spp., Phoma spp., Piedraia spp., Pneumocystis spp., Pseudallescheria spp., Pyrenochaeta spp., Rhizomucor spp., Rhizopus spp., Rhodotorula spp., Saccharorra ces spp., Scedosporium spp., Scopulariopsis spp., Sporobolomyces spp., Syncephalastrum spp., Trichoderma spp., Trichosporon spp., Ulocladium spp., Ustilago spp., Verticillium spp., Wangiella spp.
13. Peptid, der består af en sekvens A-B-C-D-C'-B'-A', hvor: enhed A består af 2 aminosyrer, og enhed A' består af 1 aminosyre, enhederne B og B' begge er Cys; hver enhed C består uafhængigt af 5 aminosyrer, begge udvalgt i gruppe (a) af hydrofobe aminosyrer, og i gruppe (b) af basiske aminosyrer eller aminosyrer, der danner hydrogenbindinger; enhed D er -Arg-Gly-, hvor: (i) de hydrofobe aminosyrer er valgt fra: Ala, Phe, lieu, Leu, Pro, Tyr, Trp og Val; (ii) de basiske aminosyrer er valgt fra: Lys, His, Arg; (iii) de aminosyrer, der danner hydrogenbindinger, er valgt fra Asn, Gin, Ser, Thr; og hvor understrukturen C-D-C' som en helhed indeholder 5 til 9 vekslingspunkter mellem aminosyre af gruppe (a) og aminosyre af gruppe (b) eller omvendt, hvor peptidet er i den cykliserede form via dannelse af en disulfidbro mellem de to enheder B, og hvor de hydrofobe aminosyrer er mellem 30 og 50 % af det totale antal af peptidets aminosyrer, hvor peptidet er valgt fra SEQ ID NO: 1-54, og homologer af hver af SEQ ID NO: 1-54, kendetegnet ved, at homologerne kun er modificeret for én aminosyre ved en hvilken som helst position mellem NO: 1 og 17, hvor modifikationen ikke involverer aminosyrer ved positionerne 3, 9, 10, 16, og modifikationen består i at substituere en aminosyre med en anden aminosyre, der hører til den samme gruppe (a) eller (b).
14. Peptid ifølge krav 13, valgt fra SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3.
15. Farmaceutisk sammensætning til anvendelse hos mennesker eller dyr, der omfatter ét eller flere peptider ifølge et hvilket som helst af kravene 1-12.
DK13828804.8T 2012-12-28 2013-12-30 Cykliske kationiske peptider med antibmikrobiel aktivitet DK2938352T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002263A ITMI20122263A1 (it) 2012-12-28 2012-12-28 Nuovi peptidi cationici ciclici ad attività antimicrobica
US201361901680P 2013-11-08 2013-11-08
PCT/IB2013/002893 WO2014102596A2 (en) 2012-12-28 2013-12-30 New cyclic cationic peptides with antimicrobial activity

Publications (1)

Publication Number Publication Date
DK2938352T3 true DK2938352T3 (da) 2018-08-20

Family

ID=48048776

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13828804.8T DK2938352T3 (da) 2012-12-28 2013-12-30 Cykliske kationiske peptider med antibmikrobiel aktivitet

Country Status (10)

Country Link
US (1) US10421782B2 (da)
EP (1) EP2938352B1 (da)
AU (1) AU2013369042B2 (da)
CA (1) CA2896697A1 (da)
DK (1) DK2938352T3 (da)
ES (1) ES2683392T3 (da)
IT (1) ITMI20122263A1 (da)
PL (1) PL2938352T3 (da)
SI (1) SI2938352T1 (da)
WO (1) WO2014102596A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298025A1 (en) * 2015-05-19 2018-03-28 Università degli Studi di Parma New amino acid sequences with microbicidal activity derived from naja atra cardiotoxin 1 (ctx-1)
CN108431019A (zh) 2015-10-07 2018-08-21 阿佩利斯制药有限公司 给药方案
MX2019012033A (es) * 2017-04-07 2019-12-05 Apellis Pharmaceuticals Inc Regímenes de dosificación y composiciones y métodos relacionados.
IT201700114664A1 (it) * 2017-10-11 2019-04-11 Univ Degli Studi Di Parma Composizioni antibatteriche ad attività potenziata
CN113750248B (zh) * 2021-09-24 2024-01-26 赣南医学院 病理识别分子-药物偶合物及其应用
WO2023092733A1 (zh) * 2021-11-25 2023-06-01 苏州慧疗生物医药科技有限公司 一种用于有效递送核酸的环状多肽载体及其变化形式
CN114989254B (zh) * 2022-06-17 2023-11-03 中山大学 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用
CN116023443B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环色-丝-缬-亮-亮肽及制备方法
CN115536734B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环色-丙-缬-亮-亮肽及制备方法
CN115636870B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环色-苏-缬-亮-亮肽及制备方法
CN115651067B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环色-丙-缬-异亮-亮肽及制备方法
CN115572324B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环色-缬-缬-丙-亮-苯丙肽及制备方法
CN115636869B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环cyclo色苏酪异亮苯丙肽及制备方法
CN115716864B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环色-缬-缬-亮-亮肽及制备方法
CN115651068B (zh) * 2022-11-24 2024-04-30 安徽农业大学 具有肝癌细胞毒性和α-葡萄糖苷酶抑制活性的环色-丙-酪-异亮-苯丙肽及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307016B1 (en) * 1995-07-06 2001-10-23 Intrabiotics Pharmaceuticals, Inc. Parevins and tachytegrins
WO1997002287A1 (en) * 1995-07-06 1997-01-23 Intrabiotics Pharmaceuticals, Incorporated Parevins and tachytegrins
AUPP051497A0 (en) 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
US6538155B1 (en) 1999-03-03 2003-03-25 Steven A. Melman Method for preparing an EDTA-Tris composition, a composition containing EDTA-Tris and uses therefor
US20030147906A1 (en) * 1999-07-21 2003-08-07 Smithkline Beecham Biologicals, S.A. Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of lgE, antagonists thereof, and their therapeutic uses
JP2005519595A (ja) * 2002-03-01 2005-07-07 ダイアックス、コープ モジュラーリコンビナトリアルディスプレイライブラリー
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7271239B2 (en) 2004-09-01 2007-09-18 The Research Foundation Of State University Of New York D-isomers of antimicrobial peptide
US8906364B2 (en) 2005-07-01 2014-12-09 Kane Biotech Inc. Antimicrobial compositions and uses thereof
DE102007044093A1 (de) 2007-09-14 2009-03-19 Phenion Gmbh & Co. Kg Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Induktion antimikrobieller Peptide in epithelialen Deckgeweben

Also Published As

Publication number Publication date
AU2013369042A1 (en) 2015-07-16
US20160083427A1 (en) 2016-03-24
CA2896697A1 (en) 2014-07-03
ES2683392T3 (es) 2018-09-26
EP2938352B1 (en) 2018-06-20
WO2014102596A2 (en) 2014-07-03
WO2014102596A3 (en) 2014-08-21
EP2938352A2 (en) 2015-11-04
ITMI20122263A1 (it) 2014-06-29
US10421782B2 (en) 2019-09-24
AU2013369042B2 (en) 2017-10-05
PL2938352T3 (pl) 2019-02-28
SI2938352T1 (sl) 2018-10-30

Similar Documents

Publication Publication Date Title
DK2938352T3 (da) Cykliske kationiske peptider med antibmikrobiel aktivitet
Kim et al. Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa
Ouhara et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cells
US11690899B2 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
EP3434287B1 (en) Short and ultra-short antimicrobial lipopeptides and use thereof
US20080234188A1 (en) Antimicrobial Peptides
Kumar et al. Antimicrobial and anti-inflammatory activities of short dodecapeptides derived from duck cathelicidin: Plausible mechanism of bactericidal action and endotoxin neutralization
Ben Hur et al. Antimicrobial peptides against multidrug-resistant Pseudomonas aeruginosa biofilm from cystic fibrosis patients
Yang et al. Antibacterial peptide BSN-37 kills extra-and intra-cellular salmonella enterica serovar typhimurium by a nonlytic mode of action
Ahn et al. Poly-lysine peptidomimetics having potent antimicrobial activity without hemolytic activity
TWI403330B (zh) 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途
WO2016184855A1 (en) New amino acid sequences with microbicidal activity derived from naja atra cardiotoxin 1 (ctx-1)
US20060258596A1 (en) Antimicrobial agents
AU2002317071A1 (en) Antimicrobial peptides
Dhingra et al. Engineering and characterization of human β-defensin-3 and its analogues and microcin J25 peptides against Mannheimia haemolytica and bovine neutrophils
CN116406282A (zh) 具有针对多药耐药性病原体的抗微生物活性的肽实体
Johnson et al. Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections
Safarpour-Dehkordi et al. A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections
He et al. A novel antimicrobial peptide derived from membrane-proximal external region of human immunodeficiency virus type 1
US20220227817A1 (en) Engineered globular endolysin, a highly potent antibacterial enzyme for multidrug resistant gram-negative bacteria
WO2017198853A1 (en) New active compounds against pathogenic microorganisms
US20220024992A1 (en) Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
Popitool Potential of antimicrobial peptides against bacterial pathogens causing bovine mastitis
Chrom Combinatorial efficacy of antimicrobial peptides and silver ions
Untverstty SCHOOL OF ENVIRONMENTAL SCIENCES